Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

DeAnna J Friedman-Klabanoff

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Current Opinion in Pediatrics|February 1, 2024
Malaria prevention in children: an updateDeAnna J Friedman-Klabanoff, Dennis Adu-Gyasi, Kwaku Poku Asante
Vaccine|September 18, 2022
Vaccine-induced seroconversion in participants in the North Carolina COVID-19 community Research PartnershipDeAnna J Friedman-Klabanoff, Ashley H Tjaden, Michele Santacatterina, et al.
The Journal of Infectious Diseases|February 8, 2022
Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Acquisition Is Associated With Individual Exposure but Not Community-Level TransmissionDeAnna J Friedman-Klabanoff, Meagan C Fitzpatrick, Meagan E Deming, et al.
The American Journal of Tropical Medicine and Hygiene|January 25, 2019
The Controlled Human Malaria Infection Experience at the University of MarylandDeAnna J Friedman-Klabanoff, Matthew B Laurens, Andrea A Berry, et al.
Vaccine|January 26, 2021
Low dose recombinant full-length circumsporozoite protein-based Plasmodium falciparum vaccine is well-tolerated and highly immunogenic in phase 1 first-in-human clinical testingDeAnna J Friedman-Klabanoff, Andrea A Berry, Mark A Travassos, et al.
Vaccines|October 28, 2025
AGS-v PLUS, a Mosquito Salivary Peptide Vaccine, Modulates the Response to <i>Aedes</i> Mosquito Bites in HumansLiam Barningham, Ian M Carr, Siân Jossi, et al.
Ebiomedicine|November 27, 2022
Safety and immunogenicity of AGS-v PLUS, a mosquito saliva peptide vaccine against arboviral diseases: A randomized, double-blind, placebo-controlled Phase 1 trialDeAnna J Friedman-Klabanoff, Megan Birkhold, Mara T Short, et al.
The Journal of Infectious Diseases|August 19, 2025
Vaccine-induced antibodies to a C-terminal Plasmodium falciparum circumsporozoite protein epitope are associated with protectionDeAnna J Friedman-Klabanoff, Travis L Jensen, Casey E Gelber, et al.
Vaccine|April 17, 2023
Factors associated with COVID-19 vaccination during June-October 2021: A multi-site prospective studyReva S Datar, Lida M Fette, Amy N Hinkelman, et al.
Plos One|September 6, 2024
Assessment of sociodemographic factors associated with time to self-reported COVID-19 infection among a large multi-center prospective cohort population in the southeastern United StatesAndrew J Beron, Joshua O Yukich, Andrea A Berry, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Current Opinion in Pediatrics|February 1, 2024
Malaria prevention in children: an updateDeAnna J Friedman-Klabanoff, Dennis Adu-Gyasi, Kwaku Poku Asante
Vaccine|September 18, 2022
Vaccine-induced seroconversion in participants in the North Carolina COVID-19 community Research PartnershipDeAnna J Friedman-Klabanoff, Ashley H Tjaden, Michele Santacatterina, et al.
The Journal of Infectious Diseases|February 8, 2022
Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Acquisition Is Associated With Individual Exposure but Not Community-Level TransmissionDeAnna J Friedman-Klabanoff, Meagan C Fitzpatrick, Meagan E Deming, et al.
The American Journal of Tropical Medicine and Hygiene|January 25, 2019
The Controlled Human Malaria Infection Experience at the University of MarylandDeAnna J Friedman-Klabanoff, Matthew B Laurens, Andrea A Berry, et al.
Vaccine|January 26, 2021
Low dose recombinant full-length circumsporozoite protein-based Plasmodium falciparum vaccine is well-tolerated and highly immunogenic in phase 1 first-in-human clinical testingDeAnna J Friedman-Klabanoff, Andrea A Berry, Mark A Travassos, et al.
Vaccines|October 28, 2025
AGS-v PLUS, a Mosquito Salivary Peptide Vaccine, Modulates the Response to <i>Aedes</i> Mosquito Bites in HumansLiam Barningham, Ian M Carr, Siân Jossi, et al.
Ebiomedicine|November 27, 2022
Safety and immunogenicity of AGS-v PLUS, a mosquito saliva peptide vaccine against arboviral diseases: A randomized, double-blind, placebo-controlled Phase 1 trialDeAnna J Friedman-Klabanoff, Megan Birkhold, Mara T Short, et al.
The Journal of Infectious Diseases|August 19, 2025
Vaccine-induced antibodies to a C-terminal Plasmodium falciparum circumsporozoite protein epitope are associated with protectionDeAnna J Friedman-Klabanoff, Travis L Jensen, Casey E Gelber, et al.
Vaccine|April 17, 2023
Factors associated with COVID-19 vaccination during June-October 2021: A multi-site prospective studyReva S Datar, Lida M Fette, Amy N Hinkelman, et al.
Plos One|September 6, 2024
Assessment of sociodemographic factors associated with time to self-reported COVID-19 infection among a large multi-center prospective cohort population in the southeastern United StatesAndrew J Beron, Joshua O Yukich, Andrea A Berry, et al.
Pageof 2